In addition, it was also shown that BH4 exerts its beneficial effects in diabetic cardiomyopathy by activating peroxisome proliferator-activated receptor-γ coactivator 1-α (PGC-1α) signaling by interacting with calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2). Here, PPARGC1A is linked to diabetic cardiomyopathy.